Evidence map›Paper›PMID 26782939›Full record

ArticleClinical cardiology2015

Treatment of Stable Angina Pectoris With Ivabradine in Everyday Practice: A Pan-Hellenic, Prospective, Noninterventional Study.

John Zarifis, Violetta Grammatikou, Manolis Kallistratos, Apostolos Katsivas, Investigators of the Prospective, Noninterventional, Observational Study of the Antianginal Efficacy of Ivabradine During a 4-Month Treatment of a Greek Population With Coronary Artery Disease

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Observational
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

John ZarifisCardiology Department, "George Papanikolaou" General Hospital, Thessaloniki, Greece.
Violetta GrammatikouMedical Department, Servier Hellas Pharmaceuticals Ltd., Athens, Greece.
Manolis KallistratosMedical Department, Servier Hellas Pharmaceuticals Ltd., Athens, Greece.
Apostolos KatsivasFirst Cardiology Department, "Korgialeneio-Benakeio E.E.S." General Hospital, Athens, Greece.
Investigators of the Prospective, Noninterventional, Observational Study of the Antianginal Efficacy of Ivabradine During a 4-Month Treatment of a Greek Population With Coronary Artery Disease
Space Hellas (Greece) · GRG. Papanikolaou General Hospital · GRHellenic Red Cross · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn coronary artery disease (CAD), medical treatment is the main clinical strategy for controlling ischemia and angina symptoms while restoring a satisfactory level of usual activities and improving quality of life (QOL). This study's purpose was to evaluate in CAD patients the antianginal efficacy of 4-month treatment with ivabradine plus a β-blocker and to record patient compliance and the effect of treatment on QOL.

methodsIn this noninterventional study, 2403 patients with chronic stable angina were prospectively studied from 245 private cardiology offices. Data were recorded at baseline and at 1 and 4 months after inclusion. Patient quality of life was assessed using the EuroQol 5 dimensions (EQ-5D) questionnaire.

resultsFrom baseline to study completion, mean heart rate decreased from 81.5 ± 9.7 bpm to 63.9 ± 6.0 bpm (P <-0.001), mean number of anginal attacks decreased from 2.0 ± 2.0 times/wk to 0.2 ± 0.6 times/wk (P < 0.001) and nitroglycerin consumption decreased from 1.4 ± 2.0 times/wk to 0.1 ± 0.4 times/wk (P < 0.001). The percentage of patients with Canadian Cardiovascular Society angina class I increased from approximately 38% (baseline) to 84% (study completion; P < 0.001). The reduction in anginal attacks, nitroglycerin consumption, and angina score was correlated with reduction in heart rate (P < 0.001). The mean EQ-5D visual analogue scale index increased by 16.1 points (P < 0.001), and compliance with treatment was high throughout the trial (96%).

conclusionsIvabradine administration on top of optimal individualized dose of β-blockers is associated with decreased anginal events and with improvement of QOL in CAD patients.

Indexed as

Adrenergic beta-AntagonistsAgedAngina, StableBenzazepinesCardiovascular AgentsDrug Therapy, CombinationFemaleGreeceHeart RateHumansIvabradineMaleMiddle AgedPatient ComplianceProspective StudiesQuality of LifeAdrenergic beta-AntagonistsBenzazepinesCardiovascular AgentsIvabradine

Identifiers

PMID26782939
PMCPMC4738471
OpenAlexW2180978761

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.